Evidence map›Paper›PMID 31664928›Full record

ArticleBMC nephrology2019

Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.

Kamyar Kalantar-Zadeh, Linda H Ficociello, Vidhya Parameswaran, Nicolaos V Athienites, Claudy Mullon, Robert J Kossmann, Daniel W Coyne

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis.International journal of nephrology and renovascular disease · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kamyar Kalantar-ZadehIrvine School of Medicine, University of California, Orange, CA, USA.
Linda H FicocielloFresenius Medical Care Renal Therapies Group, Waltham, MA, USA.
Vidhya ParameswaranFresenius Medical Care Renal Therapies Group, Waltham, MA, USA.
Nicolaos V AthienitesRenal Medical Care PC, Brockton, MA, USA.
Claudy MullonFresenius Medical Care Renal Therapies Group, Waltham, MA, USA.
Robert J KossmannFresenius Medical Care Renal Therapies Group, Waltham, MA, USA.
Daniel W CoyneWashington University School of Medicine, 660 S. Euclid Ave., CB 8129, St. Louis, MO, 63110, USA. dcoyne@wustl.edu.ORCID 0000-0001-9786-5235
Fresenius Medical Care (United States) · USSignature Healthcare Brockton Hospital · USUniversity of California, Irvine · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein.

methodsWe retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined.

resultsSO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group.

conclusionsBoth hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein.

Indexed as

Renal DialysisCohort StudiesCreatinineDietary ProteinsDrug CombinationsDrug SubstitutionFemaleFerric CompoundsHumansHypoalbuminemiaMaleMiddle AgedParathyroid HormonePhosphatesPhosphorusRenal Insufficiency, ChronicCreatinineDietary ProteinsDrug CombinationsFerric CompoundsParathyroid HormonePhosphatesPhosphorusSerum Albuminsucroferric oxyhydroxideSucroseAlbuminHemodialysisPhosphate binderPhosphorousSucroferric oxyhydroxide

Identifiers

PMID31664928
PMCPMC6820926
OpenAlexW2982583343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.